Eli Lilly's Market Position
Eli Lilly stands out as a major player in the pharmaceutical industry, with its market capitalization exceeding $800 billion. This impressive achievement is primarily due to the success of glucagon-like peptide-1 (GLP-1) agonists. Key products such as Mounjaro and Zepbound are driving a new surge of growth for the company.
Over the past year, Eli Lilly's shares have risen by 58%, showcasing remarkable performance that surpasses both the S&P 500 and Nasdaq Composite indices. With this positive momentum, some investors might be hoping for a stock split; however, given that the company hasn't carried out a stock split since October 1997, such an event seems unlikely.
Anticipating a Dividend Increase
Instead of a stock split, it seems more probable that Eli Lilly will increase its dividend. To understand the likelihood of this hike, it’s important to take a closer look at the company’s dividend history.
Eli Lilly's Dividend History
According to the financial records available on their corporate site, Eli Lilly started paying dividends back in 1972, with a quarterly dividend of only $0.01 per share. Fast forward to today, and shareholders benefit from a quarterly dividend of $1.30, equating to an annual payout of $5.20 per share.
The dividend remained steady between 2009 and 2014; however, since 2015, there has been a consistent trend of increasing dividends, largely thanks to advancements in Eli Lilly’s product line.
The Reasons Behind Dividend Increases
A key factor behind the dividend increases, especially around 2015, was the FDA’s approval of Trulicity, an important diabetes medication for Eli Lilly. Additionally, the company’s ongoing commitment to developing innovative treatments—like GLP-1 medications and recent approvals in oncology and Alzheimer's therapies—shows both their current success and promises future opportunities for growth.
Dividend Increase Timeline
Eli Lilly has developed a regular pattern for announcing dividend increases—typically during December, followed by an ex-dividend date in mid-February each year. This schedule creates a timely chance for investors who are considering the upcoming dividend increase.
The Bottom Line
While it’s uncertain whether a dividend increase will happen this December, historical trends strongly indicate that it might. Investors who are optimistic about a potential dividend hike may want to consider purchasing shares before the usual ex-dividend date.
Investing Strategy with Eli Lilly
Eli Lilly’s strong position is not just due to its innovative drug pipeline; it also presents a solid option for passive income through its dividends. The company’s emphasis on high-demand areas of treatment, such as diabetes and Alzheimer's disease, signals a promising future.
Now could be a great time to invest in Eli Lilly, regardless of whether a dividend increase is on the horizon, given the company's extensive growth potential and reliable dividend history.
Should You Invest in Eli Lilly Now?
Before making a decision to buy Eli Lilly shares, it's crucial to do your homework. While the company may not currently appear on some recommended stock lists, it demonstrates strong growth potential in various healthcare sectors that investors find attractive.
Frequently Asked Questions
What is Eli Lilly's current market capitalization?
Eli Lilly currently boasts a market capitalization of over $800 billion.
When did Eli Lilly last split its stock?
The last stock split for Eli Lilly occurred in October 1997.
How often does Eli Lilly raise its dividend?
Eli Lilly typically raises its dividend once a year, with announcements usually made in December.
What products are contributing to Eli Lilly's growth?
Major products like Mounjaro, Zepbound, and Trulicity significantly contribute to Eli Lilly's overall growth.
Is now a good time to invest in Eli Lilly?
Considering the company's growth potential and solid dividend history, many believe it is a favorable time to invest in Eli Lilly.
